SciClone Pharmaceuticals, Inc. to Present at Three Investor Conferences in November

FOSTER CITY, CA--(Marketwire - November 09, 2011) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at three upcoming investor conferences. SciClone’s executives will present a corporate overview and business update at each conference.

Cowen and Company China Opportunity Conference
Tuesday, November 15; 10 am Beijing time (Specialty Pharmaceuticals panel)
Presenter: Friedhelm Blobel, PhD, President and CEO
Tuesday, November 15; 2:30 pm Beijing time (Cross Border Collaboration panel)
Beijing, China
Presenter: Mark Lotter, CEO China Operations

Lazard Capital Markets Healthcare Conference
Wednesday, November 16; 3:30 pm ET
New York City, NY
Presenter: Gary Titus, Senior Vice President and CFO

Piper Jaffray Healthcare Conference
Wednesday, November 30; 3:30 pm ET
New York City, NY
Presenter: Friedhelm Blobel, PhD, President and CEO

Cowen and Company panels are not being webcast. To access the live audio webcast of the Lazard and Piper Jaffray presentations, please log on through a link located in the Investor Relations section of SciClone’s website at www.sciclone.com.

About SciClone
SciClone Pharmaceuticals is a revenue-generating, profitable, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone’s ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers according to the local regulatory approvals. Besides ZADAXIN, SciClone markets nearly 20 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also developing SCV-07 in a phase 2b trial for the delay to onset of oral mucositis in patients with head and neck cancer. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California. For additional information, please visit www.sciclone.com.

Ambien, Depakine, Stilnox, and Tritace are registered trademarks of Sanofi-Aventis.

Aggrastat is a registered trademark of Merck & Co., Inc.